Americas
Worldwide
Japan
Asia Pacific
Americas
Europe, Middle East, and Africa
Mizuho Bank
Mizuho Trust & Banking
Mizuho Securities
Mizuho Research & Technologies
Search
Who We Are
Our People
Diversity & Inclusion
Awards
Locations
Events
What We Do
Banking
Overview
Industry Coverage
Consumer + Retail
Energy
Financial Institutions
Financial Sponsors
Healthcare
Industrials
Power + Utilities + Infrastructure
Real Estate
Technology + Media + Telecom
Corporate Banking
Debt Capital Markets
Equity Capital Markets
Leveraged Finance
Mergers & Acquisitions
Private Capital Advisory
Mizuho | Greenhill International Presence
Regional Coverage
Restructuring
Risk Solutions
Banking Insights
Markets
Overview
Equities
Fixed Income
Futures + Options
Research
Overview
Corporate and Institutional Services
Overview
Treasury Services
Overview
Deposits
Cash Management
Commercial Card
Institutional Custody Services
Overview
Custody
Securities Lending
Insights + News
Insights
News
Press Releases
Sustainability
Sustainability
Community
Foundation
Media Relations
Press Releases-
Media Contacts & Resources-
Careers
Client Login
Futures-
US Equity Research-
Japan Equity Research-
Global Custody-
Commercial Card Portal-
Mizuho Americas
News
Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz
Amgen has ‘a lot to prove’ in the weight-loss drug category, says Mizuho’s Jared Holz
February 9, 2024
Jared Holz, Mizuho, joins ‘Closing Bell Overtime’ to talk Amgen’s obesity drug trial results.
Share This
Latest Mizuho News
See all news
Nvidia is the most compelling tech stock you can buy right now, says Mizuho’s Jordan Klein
November 18, 2025
VR has been ‘pretty big disappointment’ for Meta, says Mizuho’s Lloyd Walmsley
December 4, 2025
Walmart lifts full-year outlook, warns of higher costs
November 20, 2025
Mizuho news from around the globe
Mizuho Global News
back-to-top-blue
